GALLANT 6 tesaglitazar vs. pioglitazone

Study identifier:D6160C00030

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy when Administered to Patients with Type 2 Diabetes

Medical condition

Diabetes Mellitus, Type 2

Phase

Phase 3

Healthy volunteers

No

Study drug

Galida

Sex

All

Actual Enrollment

1450

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Aug 2004
Primary Completion Date: 01 Oct 2006
Study Completion Date: 01 Oct 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria